ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

Recruiting now · Not applicable

Conditions studied: Craniopharyngioma

In brief

This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.

Key facts

Study ID

NCT07177482

Run by

Deling Li

People needed

20

Starts

2025-07-04

Expected to finish

2026-12-31

Last updated by the study team

2025-09-17

Who can join

Age: 14 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• must be able to provide a written informed consent
• radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
• adequate clinical condition (Karnofsky performance status ≥70)

You may not qualify if…

• concomitant major central nervous system disorders
• severe hepatic or renal dysfunction
• history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
• claustrophobia precluding PET/CT or MRI examinations
• pregnancy or breastfeeding

Where it is running

• Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.